BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

Zhan Ye  ¹     Li Xi  ¹     Anindita Banerjee  ¹     Padmalatha Reddy  ¹     Engin Altintas  ²     Jacek Romatowski  ³     Jaroslaw Leszczyszyn  ⁴     Silvio Danese  ⁵     William Sandborn  ⁶     Christopher Banfield  ⁶     Jeremy Gale  ⁶     Elena Peeva  ⁶     Michael Vincent  ⁶     Craig L. Hyde  ⁶     Randy Longman  ⁷     Kenneth Hung  ⁷     Mina Hassan-Zahraee  ^7    
1 Pfizer Inc., Cambridge, United States
² Mersin University, Mersin, Turkey
³ Provincial Complex Hospital, Bialystok, Poland
⁴ Melita Medical Center, Wroclaw, Poland
⁵ IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
⁶ University of California San Diego, La Jolla, United States
⁷ Weill Cornell Medicine, New York, United States

Topic
IBD, Immunology, Nurses

Session
Understanding the biology of therapeutic response in IBD

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)